Tag Archives: Chugai Pharmaceutical

Roche’s announces favourable safety profile and effective bleed control for its Hemlibra in people with moderate or mild haemophilia A without factor VIII inhibitors

Posted on 13, December 2021 by EuropaWire PR Editors

People with moderate or mild haemophilia A have significant unmet clinical needs, as this population may not use preventative treatments due to missed or delayed diagnoses of bleeding episodes and a lack of treatment guidelines1,2 New data indicate that Hemlibra has a favourable safety profile in … Read the full press release →

Posted in Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology

Tagged American Society of Hematology, ASH, bleeding, blood clotting, blood disease, Chugai, Chugai Pharmaceutical, diagnostics, emicizumab, Genentech, haemophilia, Haemophilia A, HAVEN 6, Hemlibra®, Levi Garraway, pharmaceuticals, pharmacodynamics, pharmacokinetics, phase III HAVEN 6 study, prophylactic, Roche